Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant Anopheles gambiae apyrase
- Development stage
- Preclinical
- Lead developer
- National Institutes of Health
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
Recombinant Anopheles gambiae apyrase (rAgApyrase) is a recombinant salivary gland protein from the malaria vector mosquito *Anopheles gambiae*. It is being investigated as a transmission-blocking vaccine candidate and prophylactic agent against malaria. Naturally, salivary apyrase acts as an ATP-diphosphohydrolase that converts ATP and ADP to AMP, thereby inhibiting ADP-mediated platelet aggregation and preventing blood coagulation. It also interacts with and activates tissue plasminogen activator (tPA), enhancing the conversion of plasminogen to plasmin, which degrades fibrin and reduces blood bolus viscosity in the mosquito midgut, ultimately facilitating *Plasmodium* parasite development and transmission. Immunization with rAgApyrase induces antibodies that block these salivary functions, increasing fibrin polymerization in the mosquito midgut, inhibiting parasite development, and impairing sporozoite transmission to mammalian hosts.
- Other names
- Anopheles gambiae salivary apyraserAgApyrAgApyraserecombinant Anopheles gambiae salivary apyrase
02
Targets
PLAT (Tissue-type plasminogen activator)
Beyond the preview
Go deeper on recombinant Anopheles gambiae apyrase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant Anopheles gambiae apyrase.